Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Emergent BioSolutions Inc.NYSE: EBS

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to 4.4%

Net margin was 4.4% in Q1 FY2026, down 26.2 pp from a year earlier. On a trailing-twelve-month basis it was -1.3%, up 12.4 pp year over year. Over 3 fiscal years it widened by 26.0 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of 2.4% for the fiscal year ending Dec 2026, down from 7.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
4.4%+41.1 pp QoQ
Last fiscal yearDec 2025
7.1%+25.3 pp YoY
LTMMar 2026
-1.3%+12.4 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-26.2 pp+6.1 pp+32.3 pp
1 year+25.3 pp-4.7 pp-30.0 pp
3 years+26.0 pp+7.1 pp-18.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
7.1%
Year-over-year change
+25.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How EBS compares with its peers on the latest reported figures

  • EBS's LTM Mar 2026 net margin of -1.3% is the 5th highest of the 8 companies compared; the peer median is -1.2%.
  • Its year-over-year change of +12.4 pp is the 3rd highest of 8, against a peer median of +3.4 pp.
  • Over three fiscal years its change of +26.0 pp compares with a peer median of +3.1 pp.
EBS Competitors Peer median
Net Margin for EBS and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026121.5% +103.2 pp+173.4 pp
SIGASIGA Technologies, Inc.LTM Mar 202621.6% -18.7 pp-6.0 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 2026-0.1% +3.4 pp+3.1 pp
SNDLSNDL Inc.LTM Mar 2026-1.2% +10.4 pp+45.4 pp
EBSEmergent BioSolutions Inc.LTM Mar 2026-1.3% +12.4 pp+26.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 2026-1.8% +57.3 pp+304.0 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.1 pp-74.0 pp
PRTAProthena Corporation plcLTM Mar 2026-260.9% -181.0 pp-2303.6 pp
CMPSCOMPASS Pathways plcFY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding EBS) -1.2%+3.4 pp+3.1 pp

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.